Targeting HDAC6 Reprograms T 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.

Qiu W, Wang B, Gao Y, Tian Y, Tian M, Chen Y, Xu L, Yao T-P, Li P, Yang P. Targeting HDAC6 Reprograms T 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma. Hepatology. 2019.